SavedAdd your journal

Journals / Medicine Science / 2013 / Cilt: 2 Sayı: 3

Copeptin: May it be a novel biomarker for insulin theraphy in diabetes? An animal study

Ece Harman HARMAN
Yavuz Dodurga
Gulsah Gundogdu
Ceylan AYADA
Gulten Erken
Vural Kucukatay
Cigir Biray AVCİ
Osman Genc
Pages
701–708
Publication Date
2013-09-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Copeptin may be considered as a new tool for the comparison of the efficiencies of new therapeutic modalities in diabetes.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Copeptin is a marker about prognosis of acute illnesses, generally.
📊
Key Findings & Data:Healthy male Wistar rats, about 3 months old, weighing 200 "250 g, were obtained from University Animal House.
💡
Conclusion & Impact:Copeptin may be considered as a new tool for the comparison of the efficiencies of new therapeutic modalities in diabetes.
🔬Design:Lab & Field Experiment
📍Scope:Comprehensive Sample
⚙️Variables:Copeptin · insulin · diabetes

Abstract

Copeptin is a marker about prognosis of acute illnesses, generally. It may be also an indicator associated with treatment of chronic diseases. We aimed to evaluate copeptin levels in rat models with stress, diabetes, diabetes+insulin. Healthy male Wistar rats, about 3 months old, weighing 200 "250 g, were obtained from University Animal House. They were housed in small cages at standard conditions (24 ± 2°C and 50 ± 5% humidity) with a 12 h light/dark cycle and were fed ad libitum with standard rat chow and tap water. Rats were divided into 4 groups: 8 control (C), 8 diabetic (D), 8 diabetic+insulin (DI) and 8 stress (S) rats. Quantitative measurement of Copeptin was performed using the ELISA method (Uscn Life Sciences, USA), according to the manufactur ers instructions. Copeptin level was statistically significant decreased in D+I groups. There was no difference in copeptin level between the S, D, and C groups. Copeptin may be considered as a new tool for the comparison of the efficiencies of new therapeutic modalities in diabetes.

Özet

Copeptin is a marker about prognosis of acute illnesses, generally. It may be also an indicator associated with treatment of chronic diseases. We aimed to evaluate copeptin levels in rat models with stress, diabetes, diabetes+insulin. Healthy male Wistar rats, about 3 months old, weighing 200 "250 g, were obtained from University Animal House. They were housed in small cages at standard conditions (24 ± 2°C and 50 ± 5% humidity) with a 12 h light/dark cycle and were fed ad libitum with standard rat chow and tap water. Rats were divided into 4 groups: 8 control (C), 8 diabetic (D), 8 diabetic+insulin (DI) and 8 stress (S) rats. Quantitative measurement of Copeptin was performed using the ELISA method (Uscn Life Sciences, USA), according to the manufactur ers instructions. Copeptin level was statistically significant decreased in D+I groups. There was no difference in copeptin level between the S, D, and C groups. Copeptin may be considered as a new tool for the comparison of the efficiencies of new therapeutic modalities in diabetes.

🔖

Cite This Article

HARMAN, E. H., Dodurga, Y., Gundogdu, G., AYADA, C., Erken, G., Kucukatay, V., AVCİ, C. B., Genc, O. (2013). Copeptin: May it be a novel biomarker for insulin theraphy in diabetes? An animal study. Medicine Science, Cilt: 2 Sayı: 3, 701–708. https://ajindex.com/articles/1003295

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Holwerda DA. A glycopeptide from the posterior lobe of pig pituitaries. Isolation and characterization. Eur J Biochem. 1972;28(3):334–9.
  2. Struck J, Morgenthaler NG, Bergmann A. Copeptin, a stable peptide derived from the vasopressin precursor, is elevated in serum of sepsis patients. Peptides. 2005;26(12):2500–4.
  3. Morgenthaler NG, Struck J, Alonso C, Bergmann A. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem. 2006; 52(1):112–9.
  4. KatanM, Müler B, Crain MC. Copeptin: A new and promising diagnostic and prognostic marker. Critical Care. 2008;12(2):117-8.
  5. Katan M, Morgenthaler N, Widmer I, Puder JJ, Konig C, Muller B, Christ-Crain M. Copeptin, a stable peptide derived from the vasopressin precursor, correlates with the individual stress level. Neuro Endocrinol Lett. 2008;29(3):341-6.
  6. Morgenthaler NG, Struck J, Jochberger S, Dunser MW. Copeptin: Clinical use of a new biomarker. Trends in endocrinology and metabolism: TEM. 2008,19(2):43-9.
  7. Katan M, Fluri F, Morgenthaler NG, Schuetz P, Zweifel C, Bingisser R, MüllerK, Meckel S, Gass A, Kappos L, Steck AJ, Engelter ST, Müller B, Christ-Crain M. Copeptin: a novel, independent prognostic marker in patients with ischemic stroke. Ann Neurol. 2009:66(6):799-808. Antoni FA. Vasopressinergic control of pituitary adrenocorticotropin secretioncomes of age. Front Neuroendocrinol. 1993;14(2):76-122. Keppens S, de Wulf H. The nature of the hepatic receptors involved in vasopressininduced glycogenolysis. Biochim Biophys Acta. 1979;588(1):63-9.
  8. Abu-Basha EA, Yibchok-Anun S, Hsu WH. Glucose dependency of argininevasopressin-induced insulin and glucagon release from the perfused rat pancreas.Metabolism. 2002;51(9):1184-90.
  9. Struck J, Morgenthaler NG, Bergmann A. Copeptin, a stable peptide derived fromthe vasopressin precursor, is elevated in serum of sepsis patients. Peptides. 2005;26(12):2500-4. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 2003;26(Suppl. 1):S5-20. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest. 2005;115(5):1111-9.
  10. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, CreagerMA, Deanfield J, Drexler H, Gerhard-Herman M, Herrington D, Vallance P, Vita J,Vogel R. International Brachial Artery Reactivity Task Force. Guidelines for theultrasound assessment of endothelial-dependent